Search

Welcome to the Official PhaZZer Store

Featured products
News
OMAHA, Neb., Oct. 16, 2019 (GLOBE NEWSWIRE) -- AXON / TASER’S (AAXN) APPEAL REJECTED BY US PATENT TRIAL AND APPEAL BOARD’S AFFIRMANCE OF EXAMINER’S INVALIDATION OF ALL US PATENT NO. 7,234,262 CLAIMS
OMAHA, Neb., Oct. 15, 2019 (GLOBE NEWSWIRE) -- PhaZZer announces that TASER/AXON (AAXN) filed a (now withdrawn) unsupported lawsuit in what appeared to be a last-ditch attempt to stop the PhaZZer Enforcer CEW and cartridges’ entry as the only viable and accepted competitor by US Law Enforcement.
JUDGE BYRON OF THE FEDERAL DISTRICT COURT OF CENTRAL FLORIDA ON PAGE 12 OF THE SANCTIONS ORDER ISSUED IN THE CASE OF AXON (AAXN) formally TASER INTERNATIONAL -v- PHAZZER ELECTRONICS STATED….. “the Phazzer Enforcer CEW, and any other conducted electrical weapon (“CEW”) or device which infringed upon claim 13 of the TASER ‘262 Patent, and any device not colorably different from the Enforcer CEW. The effect of this injunction shall continue through October 14, 2019, the expiration of the TASER ‘262 Patent.”
AXON ENTERPRISE MARKET CAP: $4.0B (MID CAP) EXCHANGE: NASDAQ TICKER: AAXN HQ: SCOTTSDALE, AZ SECTOR: INDUSTRIAL GOODS 17 ACTIVIST INSIGHT MONTHLY AUGUST 2019 | WWW.ACTIVISTINSIGHT.COM ...CLAIMING THE BUSINESS WILL FACE A SLOWDOWN IN GROWTH. ELANA DURÉ EXPLAINS WHY THE PAIR THINK AXON IS “A STUNNING SHORT.”
Summary Spruce Point has learned of an imminent renewed competitive threat to Axon. The Street is not yet aware. PhaZZer Global is set to launch a new CEW in October 2019. Axon's injunction for patent 262 expires Oct 2019. We expect PhaZZer's new product will be 30% cheaper, forcing gov't agencies to evaluate cost and performance of Taser v PhaZZer. Axon's contract terms allow cancellation with limited restrictions should customers decide to switch. Analysts expect 10% Taser growth in 2020. But just modest assumptions for market share loss, and price concessions, will cause a big miss. With Axon now trading at the average analyst consensus target of $73, the risk/reward is highly unfavorable.
The Axon patent expiry is confirmed at Google Patents, opening the door for new, and existing competition that have been waiting on the sidelines patiently while perfecting their product, price and distribution strategy
All it takes are very modest market penetration assumptions by PhaZZer and/or modest price concessions by Taser, and $AAXN will wildly miss street estimates that are calling for 10% Taser revenue growth
Tweeted by Spruce Point Capital 21 June 2019 PhaZZer had strong market traction before the $AAXN injunction...
NEWS PROVIDED BY Spruce Point Capital Management, LLC NEW YORK, June 19, 2019 /PRNewswire/ -- Report entitled "A Stunning Short" outlines how Axon, formerly known as Taser International, faces 40-60% downside risk to approximately $27.50 to $40.00 per share due to its inability to gain traction on proposed software offerings, aggressive revenue recognition and future margin erosion, and a valuation predicated on management's unrealistic attempt at transforming the company into a comprehensive SaaS business.
PhaZZer IP, LLC. Launches Licensed U.S. Suppliers in Competition to Axon Enterprises, Inc. (AAXN) Single Shot, Cartridges